This decommissioned ERA site remains active temporarily to support our final migration steps to https://ualberta.scholaris.ca, ERA's new home. All new collections and items, including Spring 2025 theses, are at that site. For assistance, please contact erahelp@ualberta.ca.
Search
Skip to Search Results-
Deciphering the Biological Basis of Acute Myeloid Leukemia Relapse Using a Novel In-Vitro Study Model
DownloadSpring 2024
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy associated with a poor clinical outcome that is largely attributed to disease relapses. Treatment options for relapsed AML patients are limited; after relapse, the median survival is only ~6 months. The biology underlying...
-
Evaluation of Targeted Selective Inhibitors to Enhance Temozolomide Treatment Sensitivity in Acute Myeloid Leukemia
DownloadSpring 2024
Temozolomide (TMZ) is an alkylating agent with limited activity in acute myeloid leukemia (AML). The DNA repair enzyme O6-methylguanine methyltransferase (MGMT) enhances tumor cell resistance to TMZ. B-cell lymphoma-2 (BCL-2) and mouse double minute 2 homology (MDM2) are proteins involved in AML...
-
Spring 2021
The nuclear transcription factor, Signal Transducer and Activator of Transcription 5 (STAT5) is one of the key drivers of Acute Lymphoblastic Leukemia (ALL), the most common childhood cancer, that promotes initiation, maintenance and progression to more aggressive stages of the malignancy by...